Other

Fresenius Ag

Frank Bepperling

Klaus Sommermeyer

Wolfram Eichner

Klaus Henning

Burghard Weidler

Jens Opitz

Use of hemoglobin derivatives for determining plasma and/or blood volume

The use of a hydroxyethyl starch specification with a molecular weight M.sub.W of 110,000 to 150,000, a substitution level MS of 0.38 to 0.5, a substitution level DS of 0.32 to 0.45, and a C.sub.2 /C.sub.6 ratio from 8 to 20 for improvement of microcirculation in a peripheral arterial circulation disorder, in particular in already existing peripheral arterial occlusive disease in Stage II according to Fontaine. This hydroxyethyl starch specification can be used in suitable concentrations, e.g., as 6 wt.-% or 10 wt.-% solution, whereby these solutions optionally contain conventional adjuvants and additives.

Use of hydroxyethyl starch for improvement of microcirculation

Growing community of inventors

Bad Nauheim, Germany

Frank Bepperling